{"generic":"Sevelamer Hydrochloride","drugs":["Renagel","Sevelamer Hydrochloride"],"mono":{"0":{"id":"jtljs0","title":"Generic Names","mono":"Sevelamer Hydrochloride"},"1":{"id":"jtljs1","title":"Dosing and Indications","sub":{"0":{"id":"jtljs1b4","title":"Adult Dosing","mono":"<ul><li>safety and efficacy in end stage renal disease (ESRD) patients who are not on hemodialysis have not been established<\/li><li><b>End stage renal disease - Hemodialysis - Hyperphosphatemia:<\/b> serum phosphorus between 5.5 and 7.5 mg\/dL, initial, 800 mg ORALLY 3 times a day with meals<\/li><li><b>End stage renal disease - Hemodialysis - Hyperphosphatemia:<\/b> serum phosphorus between 7.5 and 9 mg\/dL, initial, 1200-1600 mg ORALLY 3 times a day with meals<\/li><li><b>End stage renal disease - Hemodialysis - Hyperphosphatemia:<\/b> serum phosphorus greater than 9 mg\/dL, 1600 mg ORALLY 3 times a day with meals<\/li><li><b>End stage renal disease - Hemodialysis - Hyperphosphatemia:<\/b> dose titration, serum phosphorus greater than 5.5 mg\/dL, increase by 400 mg per meal at 2 week intervals (max dose 4 g); serum phosphorus 3.5-5.5 mg\/dL, maintain current dose; serum phosphorus less than 3.5 mg\/dL, decrease by 400 mg per meal<\/li><\/ul>"},"1":{"id":"jtljs1b5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established "},"3":{"id":"jtljs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>End stage renal disease - Hemodialysis - Hyperphosphatemia<br\/>"}}},"3":{"id":"jtljs3","title":"Contraindications\/Warnings","sub":[{"id":"jtljs3b9","title":"Contraindications","mono":"bowel obstruction <br\/>"},{"id":"jtljs3b10","title":"Precautions","mono":"<ul><li>swallowing disorders; dysphagia and esophageal tablet retention have been reported, some severe requiring intervention and hospitalization; consider change to suspension<\/li><li>bowel obstruction and intestinal perforation have been reported<\/li><li>report known or suspected adverse events to the United States Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jtljs3b11","title":"Pregnancy Category","mono":"Sevelamer: C (FDA)<br\/>"},{"id":"jtljs3b12","title":"Breast Feeding","mono":"Sevelamer: Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"jtljs4","title":"Drug Interactions","sub":{"2":{"id":"jtljs4b15","title":"Moderate","mono":"<ul><li>Ciprofloxacin (established)<\/li><li>Levothyroxine (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><\/ul>"}}},"5":{"id":"jtljs5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Abdominal pain (9%), Constipation (8%), Diarrhea (19%), Flatulence (8%), Indigestion (16%), Nausea (20%), Vomiting (22%)<br\/><b>Serious<\/b><br\/><b>Gastrointestinal:<\/b>Bowel obstruction, Perforation of intestine, Peritonitis (8%)<br\/>"},"6":{"id":"jtljs6","title":"Drug Name Info","sub":{"0":{"id":"jtljs6b17","title":"US Trade Names","mono":"Renagel<br\/>"},"2":{"id":"jtljs6b19","title":"Class","mono":"<ul><li>Bile Acid Sequestrant<\/li><li>Phosphate Binder<\/li><\/ul>"},"3":{"id":"jtljs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jtljs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jtljs7","title":"Mechanism Of Action","mono":"Sevelamer hydrochloride, a polymeric phosphate binder, inhibits intestinal phosphate absorption and reduces low-density lipoprotein (LDL) and total serum cholesterol levels.<br\/>"},"8":{"id":"jtljs8","title":"Pharmacokinetics","sub":{"0":{"id":"jtljs8b23","title":"Absorption","mono":"<ul><li>Bioavailability: oral: not systemically absorbed<\/li><li>Effects of food: should be given with meals but not with enteral nutrition<\/li><\/ul>"},"3":{"id":"jtljs8b26","title":"Excretion","mono":"Fecal: 100% <br\/>"}}},"9":{"id":"jtljs9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>medications whose bioavailability, safety, and efficacy may be significantly affected by concurrent administration with sevelamer should be given at least 1 h before or 3 h after sevelamer<\/li><li>swallow intact tablets; do not crush, chew, break into pieces, or take tablets apart prior to administration<\/li><li>take with meals<\/li><\/ul>"},"10":{"id":"jtljs10","title":"Monitoring","mono":"<ul><li>serum phosphorus target level 5.5 mg\/dL or less<\/li><li>folic acid, vitamins D, E, and K levels<\/li><li>serum bicarbonate, chloride levels<\/li><\/ul>"},"11":{"id":"jtljs11","title":"How Supplied","mono":"<b>Renagel<\/b><br\/>Oral Tablet: 400 MG, 800 MG<br\/>"},"13":{"id":"jtljs13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause hypotension, dyspepsia, nausea, or vomiting.<\/li><li>Advise patient to report signs\/symptoms of thrombotic disorder.<\/li><li>Patient should take drug with meals and adhere to prescribed diet.<\/li><\/ul>"}}}